文献速递炎症性肠病

生物制剂初治溃疡性结肠炎:生物制剂与小分子药物起效速度比较

Comparing Onset of Efficacy of Biologic and Small Molecule Therapies in Biologic-Naïve Ulcerative Colitis: A Post-Hoc Analysis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2026-06-04

该事后分析利用11项随机对照试验的个体数据,纳入3573例生物制剂初治的中重度溃疡性结肠炎患者,比较多种先进疗法的起效与诱导疗效。第2周时乌帕替尼和英夫利西单抗的PRO-2应答率最高,调整后乌帕替尼早期应答优于英夫利西单抗,而米吉珠单抗、阿达木单抗和乌司奴单抗较低。诱导后除乌帕替尼外,其他疗法第8周PRO-2应答均显著低于英夫利西单抗。

要点

  • 乌帕替尼第2周PRO-2应答率65%,英夫利西单抗36.5%,为起效最快药物。
  • 调整后乌帕替尼早期应答优于英夫利西单抗(aOR 3.57),米吉珠单抗、阿达木单抗、乌司奴单抗较低。
  • 诱导后除乌帕替尼外,其他疗法第8周PRO-2应答均显著低于英夫利西单抗。

核心结论

  • 在生物制剂初治中重度溃疡性结肠炎患者中,乌帕替尼和英夫利西单抗起效最快且诱导后临床应答最高。

研究设计与样本

  • 事后分析,利用11项随机对照试验的个体参与者数据,纳入3573例生物制剂初治中重度溃疡性结肠炎患者。
  • 评估英夫利西单抗、阿达木单抗、戈利木单抗、维得利珠单抗、乌司奴单抗、米吉珠单抗、托法替布或乌帕替尼标准诱导剂量。
  • 主要结局为第2周早期PRO-2应答(排便频率和直肠出血评分较基线下降≥50%),采用logistic回归调整基线协变量,以英夫利西单抗为活性对照。

主要发现

  • 第2周乌帕替尼PRO-2应答率65%,英夫利西单抗36.5%,为最高。

临床怎么用

  • 对于生物制剂初治中重度溃疡性结肠炎需快速症状控制者,可优先考虑乌帕替尼或英夫利西单抗。

局限性

  • 为事后分析,证据级别低于预设主要分析。
  • 仅纳入生物制剂初治患者,结果不能外推至经治人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Achieving rapid symptom control is important in managing ulcerative colitis. However, data regarding speed of onset of therapies among these patients remains limited. We compared the onset and induction efficacy of advanced therapies in biologic-naïve patients with moderate to severe ulcerative colitis. METHODS: This post-hoc analysis utilized individual participant-level data from 11 randomized controlled trials. We evaluated biologic-naïve patients receiving standard induction doses of infliximab, adalimumab, golimumab, vedolizumab, ustekinumab, mirikizumab, tofacitinib, or upadacitinib. The primary outcome was early Patient-Reported Outcome-2 response, defined as ≥50% reduction in stool frequency and rectal bleeding scores at week 2. Secondary outcomes included post-induction Patient-Reported Outcome-2 response and remission. Logistic regression models adjusted for baseline covariates were used with infliximab as the active comparator. RESULTS: The analysis included 3573 biologic-naïve patients with moderate to severe ulcerative colitis. At week 2, upadacitinib (65%) and infliximab (36.5%) demonstrated the highest Patient-Reported Outcome-2 response rates. In adjusted analyses compared to infliximab, upadacitinib demonstrated the highest rate of Patient-Reported Outcome-2 response (adjusted odds ratio, 3.57; 95% confidence interval, 2.40-6.20; P = .029), whereas mirikizumab (adjusted odds ratio, 0.46; 95% confidence interval, 0.32-0.66; P < .001), adalimumab (adjusted odds ratio, 0.67; 95% confidence interval, 0.46-0.97; P = .035), and ustekinumab (adjusted odds ratio, 0.60; 95% confidence interval, 0.38-0.96; P = .031) demonstrated lower odds of early response. At postinduction, all therapies except for upadacitinib demonstrated significantly lower odds of Patient-Reported Outcome-2 response compared with infliximab at week 8 (all P < .01). A significantly lower odds of postinduction Patient-Reported Outcome-2 remission was observed for upadacitinib (adjusted odds ratio, 0.48; 95% confidence interval, 0.34-0.69; P < .001), adalimumab (adjusted odds ratio, 0.17; 95% confidence interval, 0.11-0.25; P < .001), and golimumab (adjusted odds ratio, 0.46; 95% confidence interval, 0.26-0.74; P = .001). CONCLUSIONS: Among biologic-naïve patients with moderate to severe ulcerative colitis, upadacitinib and infliximab demonstrated the most rapid onset of action and highest postinduction clinical response.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Wong ECL, Jairath V, Dulai PS, et al. Comparing Onset of Efficacy of Biologic and Small Molecule Therapies in Biologic-Naïve Ulcerative Colitis: A Post-Hoc Analysis. Clin Gastroenterol Hepatol. 2026. PMID: 42248438. doi:10.1016/j.cgh.2026.05.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。